Evidence map›Paper›PMID 41545714›Full record

ArticleNature cancer2026

Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy.

Xiaohong Chen, Minqi Yang, Yuxuan Chen, Yao Zhang, Shuang Wang, Jiaqi Meng, Zunqiao Zhu, Wen Li, Wei Wei, Yuan Ping and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaohong Chen *Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Minqi Yang *Zhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuxuan ChenCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. colinchen@zju.edu.cn.ORCID http://orcid.org/0000-0003-0727-1834
Yao ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Shuang WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China.ORCID http://orcid.org/0000-0002-9189-602X
Jiaqi MengState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China.
Zunqiao ZhuZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wen LiZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wei WeiState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, China. weiwei@ipe.ac.cn.ORCID http://orcid.org/0000-0002-6244-3187
Yuan PingCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. pingy@zju.edu.cn.ORCID http://orcid.org/0000-0003-2571-7721
Tingbo LiangZhejiang Provincial Key Laboratory of Pancreatic Disease, MOE Joint International Research Laboratory of Pancreatic Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. liangtingbo@zju.edu.cn.ORCID http://orcid.org/0000-0003-0143-3353

Funding

National Natural Science Foundation of China (National Science Foundation of China) T2225021National Natural Science Foundation of China (National Science Foundation of China) U20A20378
6 · The paper itself

Abstract

Systemic delivery of oncolytic viruses (OVs) is limited by neutralizing antibodies and poor intratumoral bioavailability. Here we developed genetically engineered, immune-compatible cell membranes expressing a chimeric antigen receptor to cloak OVs, creating a tumor-targeted viral delivery platform (iNV-GOV) that shields virions from immune recognition while guiding them to tumors. The OV payload encodes an N-terminal gasdermin under a heat-shock promoter enabling ultrasound-induced mild hyperthermia to trigger tumor-specific pyroptosis, accelerate oncolysis and promote rapid viral release from lysed tumor cells, thereby amplifying infection of neighboring tumor populations. Following systemic administration, iNV-GOV efficiently targets and infects tumor cells, induces pyroptosis upon ultrasound activation and elicits robust antitumor immunity in patient-derived xenograft models in humanized mice. Collectively, this systemically injectable, tumor-targeted OV platform enables rapid and continuous intratumoral viral propagation and represents a promising strategy for treating a wide range of cancers.

Indexed as

Genetic EngineeringNeoplasmsOncolytic VirotherapyOncolytic VirusesPyroptosisAnimalsCell Line, TumorFemaleHumansMiceXenograft Model Antitumor Assays

Identifiers

PMID41545714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.